BR0209869A - Identificação de fungo parasìtico do organismo e seu tratamento - Google Patents

Identificação de fungo parasìtico do organismo e seu tratamento

Info

Publication number
BR0209869A
BR0209869A BR0209869-5A BR0209869A BR0209869A BR 0209869 A BR0209869 A BR 0209869A BR 0209869 A BR0209869 A BR 0209869A BR 0209869 A BR0209869 A BR 0209869A
Authority
BR
Brazil
Prior art keywords
treatment
organism
hericum
identification
peniophora
Prior art date
Application number
BR0209869-5A
Other languages
English (en)
Inventor
Roumen Antonov
Original Assignee
Roumen Antonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0106775A external-priority patent/FR2825024B1/fr
Priority claimed from FR0109203A external-priority patent/FR2827173B3/fr
Application filed by Roumen Antonov filed Critical Roumen Antonov
Publication of BR0209869A publication Critical patent/BR0209869A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

"IDENTIFICAçãO DE FUNGO PARASìTICO DO ORGANISMO E SEU TRATAMENTO". Um objeto da presente invenção e o uso de antifungicidas, em particular aqueles ativos nos fungos do gênero Cândida, para a preparação de medicamentos pretendidos para a prevenção ou tratamento de patologias ligadas à presença no organismo humano ou animal dos seguintes fungos: Entomocorticum sp., Stereum annosum, Phellinus igniarus, Peniophora pithya, Peniophora piceae, Xilaria longipes, Rosellinia arcuata, Rosellinia necatrix, Multiclavula vernalis, Hericum coralloides, Hericlum abietis, Hericum erinaceum, Hericum rivularis, Tricholama terreum.
BR0209869-5A 2001-05-23 2002-05-23 Identificação de fungo parasìtico do organismo e seu tratamento BR0209869A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0106775A FR2825024B1 (fr) 2001-05-23 2001-05-23 Identification de champignons parasites de l'organisme, et leur traitement
FR0109203A FR2827173B3 (fr) 2001-07-11 2001-07-11 Identification de champignons parasites de l'organisme, et leur traitement
PCT/FR2002/001739 WO2002094287A2 (fr) 2001-05-23 2002-05-23 Identification de champignons parasites de l'organisme, et traitement des maladies liees

Publications (1)

Publication Number Publication Date
BR0209869A true BR0209869A (pt) 2004-04-20

Family

ID=26213022

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209869-5A BR0209869A (pt) 2001-05-23 2002-05-23 Identificação de fungo parasìtico do organismo e seu tratamento

Country Status (18)

Country Link
US (1) US20040198633A1 (pt)
EP (1) EP1389120B1 (pt)
KR (1) KR20040018377A (pt)
CN (1) CN1518451A (pt)
BG (1) BG66299B1 (pt)
BR (1) BR0209869A (pt)
CA (1) CA2448045A1 (pt)
CZ (1) CZ20033145A3 (pt)
EE (1) EE200300572A (pt)
HU (1) HUP0400035A2 (pt)
IL (1) IL158967A0 (pt)
NO (1) NO20035188D0 (pt)
NZ (1) NZ529764A (pt)
PL (1) PL367700A1 (pt)
RU (1) RU2003136777A (pt)
SK (1) SK14372003A3 (pt)
WO (1) WO2002094287A2 (pt)
ZA (1) ZA200309122B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
CN103044376A (zh) * 2012-12-15 2013-04-17 青岛农业大学 桑黄菌中吡喃酮的分离技术
CN116515641B (zh) * 2023-04-26 2023-09-29 吉林农业大学 一株珊瑚状猴头菌及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786781A (en) * 1954-11-04 1957-03-26 Olin Mathieson Process of recovering nystatin
US2908611A (en) * 1954-12-28 1959-10-13 Olin Mathieson Amphotericin b, its production, and its salts
US3714348A (en) * 1970-12-02 1973-01-30 Schmid Inc Julius Method for controlling absorption of cholesterol
US4025620A (en) * 1975-10-22 1977-05-24 Leo Pharmaceutical Products Ltd., A/S Treatment of canine otitis and composition therefor
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
GB9320744D0 (en) * 1992-11-04 1993-12-01 Zeneca Ltd Oxa and thiadiazole derivatives
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
EP0771205A2 (de) * 1994-06-28 1997-05-07 Dr. Zerle Gmbh Neue klinische anwendungen von polyen-makroliden
US5914239A (en) * 1995-11-15 1999-06-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnosis of fungal infections, and a chitin-binding lectin useful in such diagnoses
WO2001014592A2 (en) * 1999-08-25 2001-03-01 Clarity Biosciences, Inc. Identifying organisms by detecting intronic nucleic acid or encoded proteins

Also Published As

Publication number Publication date
CA2448045A1 (fr) 2002-11-28
EP1389120B1 (fr) 2012-08-01
US20040198633A1 (en) 2004-10-07
WO2002094287A3 (fr) 2003-09-25
EP1389120A2 (fr) 2004-02-18
BG108375A (bg) 2005-01-31
BG66299B1 (bg) 2013-03-29
ZA200309122B (en) 2004-11-24
PL367700A1 (en) 2005-03-07
SK14372003A3 (sk) 2004-05-04
KR20040018377A (ko) 2004-03-03
CN1518451A (zh) 2004-08-04
NO20035188D0 (no) 2003-11-21
CZ20033145A3 (cs) 2004-10-13
IL158967A0 (en) 2004-05-12
RU2003136777A (ru) 2005-04-10
WO2002094287A2 (fr) 2002-11-28
NZ529764A (en) 2005-08-26
EE200300572A (et) 2004-02-16
HUP0400035A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
Anton et al. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism
Mens et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
BR0011286A (pt) Preparado farmacêutico com a substância ativa diamorfina e seu emprego em um processo para tratamento de vìcio em ópio
Manivannan et al. The rise and fall of chloroquine/hydroxychloroquine as compassionate therapy of COVID-19
Gupta et al. In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum
McPherson et al. Investigate oral zinc as a prophylactic treatment for those at risk for COVID-19
BRPI0608431B8 (pt) composto contendo boro, e, formulação farmacêutica
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
Corral et al. In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum
Greay et al. Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil
Gosling et al. Presumptive treatment of fever cases as malaria: help or hindrance for malaria control?
BRPI0013010B8 (pt) formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina
Pradines et al. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs
Sadjjadi et al. Comparative clinical trial of mebendazole and metronidazole in giardiasis of children
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
Adjei et al. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries
Sargin et al. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
Li et al. Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo
Izumi et al. Efficacy of an emollient containing diethylene glycol/dilinoleic acid copolymer for the treatment of dry skin and pruritus in patients with senile xerosis
Castellarnau et al. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial
Bonilla-Ramírez et al. Primaquine–quinoxaline 1, 4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species
Adewole et al. Antioxidant defense system induced by cysteine-stabilized peptide fraction of aqueous extract of Morinda lucida leaf in selected tissues of Plasmodium berghei-infected mice
BR0209869A (pt) Identificação de fungo parasìtico do organismo e seu tratamento
Derouin et al. Anti-Toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro
Eccles et al. Treatment of acute cough due to the common cold: multi-component, multi-symptom therapy is preferable to single-component, single-symptom therapy—a pro/con debate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2309 DE 07/04/2015.